Jagsonpal Pharma Allots 2.96 Lakh Equity Shares Under ESOP 2022
Jagsonpal Pharmaceuticals Limited allotted 2,96,320 equity shares under its ESOP 2022 plan on June 4, 2026. This increased the paid-up share capital to Rs. 13,16,70,940 from Rs. 13,10,78,300.
The allotment of shares under an ESOP plan is a standard practice and has a minimal impact on the overall business operations or market perception.
The announcement is a routine ESOP allotment and does not significantly impact the company's financial performance or strategic direction.
Jagsonpal Pharmaceuticals Limited has announced the allotment of 2,96,320 Equity Shares of Rs. 2/- each under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 (JPL ESOP 2022). These shares were issued to eligible employees upon the exercise of vested options and will rank pari-passu with the existing equity shares of the company.
The allotment has resulted in an increase in the company's paid-up share capital. Prior to this allotment, the paid-up share capital was Rs. 13,10,78,300, comprising 6,55,39,150 equity shares of Rs. 2/- each. Post-allotment, the paid-up share capital has increased to Rs. 13,16,70,940, consisting of 6,58,35,470 equity shares of Rs. 2/- each.
The exercise prices for the shares varied: Rs. 94.00/- for 2,28,000 equity shares, Rs. 113.60/- for 59,920 equity shares, and Rs. 115.60/- for 8,400 equity shares. Correspondingly, the premium per share was Rs. 92.00/-, Rs. 111.60/-, and Rs. 113.60/- for these tranches, respectively. The shares were issued on June 4, 2026.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under designated person disclosures. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.